Clinical correlates of sarcopenia and falls in Parkinson's disease.
This note indexes a cited or audit-added source. It may be an original study, review, guideline, form or methods reference. Treat the specific design and the evidence below as authoritative; a source note is not automatically a primary study.
DOI: 10.1371/journal.pone.0227238
Bibliographic record from the original reports
Access labels embedded in these original reference strings are historical. Current access and exact checked components are stated separately below.
Lima DP, de Almeida SB, Bonfadini JC, de Luna JRG, de Alencar MS, Pinheiro-Neto EB, et al. Clinical correlates of sarcopenia and falls in Parkinson's disease. PLoS One. 2020;15(3):e0227238. DOI 10.1371/journal.pone.0227238
Conditions: COND-PD Parkinson’s disease
Scoped audit evidence
These are source- and component-level audit summaries as of 3 October 2026. Access and comparison scope can differ by report; none certifies every result or the underlying raw data.
Parkinson’s disease — strength
- access status: full_main_text_available
STR-58-02
STR-58-01
Limitations: Only current scoped checks; archived captures not authenticated against live originals.
Parkinson’s disease strength
- current access: full_main_text_available
- primary version: PMC full article; version not independently compared to publisher PDF
Parkinson’s disease strength component — Cross-sectional sarcopenia/falls construct and grip result
Tables match 218 PD participants, 210 with falls data, 92 past-six-month fallers and grip medians 21.3/22.0 kg, p=.291. Methods confirms ON testing and better-hand trial mean; final model retains SARC-F and duration.
Source locator: Methods; Tables 1/3/4
Limitations: AI-assisted source comparison; no raw-data verification.
Parkinson’s disease strength component — Sarcopenia constructs and SARC-F content
Lima Methods distinguishes SARC-F screening from low measured strength; its five items explicitly cover strength, walking, chair rise, stairs and falls. The 2019 EWGSOP 2 primary indexed abstract (DOI 10.1093/ageing/afy 169, PMID 30312372) independently supports low strength as the principal indicator, low muscle quantity/quality for confirmation and poor physical performance for severity. Report correctly separates those constructs and warns about shared outcome content.
Source locator: https://doi.org/10.1371/journal.pone.0227238; audit evidence record Assessment of Sarcopenia; archived source evidence (ancillary consensus source)
Limitations: AI-assisted source comparison; no raw-data verification.
Reports citing this source
- Strength muscle power and rapid force production assessment in Parkinson’s disease · reference 58 · original reference
Update record
- 2026-10-03: Created from the supplied reports and final scoped audit. New evidence should be appended with source version, access date, exact locator and affected report links.
Updating the wiki · Evidence and status guide